Form 4 for RGNX REGENXBIO Inc.
Accepted 2024-07-30 00:00:00 ET · period of report 2024-07-29 · accession 0001562180-24-005874 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2024-07-30 | 2024-07-29 | RGNX | Simpson Curran | CEO, Dir | S - Sale | $15.04 | -9,648 | 170.1K | -5% | -$145.1K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-07-29 | S | D | 9,648 | $15.04 | 170,137 | D | — | — | (F2) This transaction was executed in multiple trades at prices ranging from $15.00 to $15.20. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |